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Figure	3.9.	TIA-1	and	arsenite	enhance	the	size	of	autophagosomes.	Transfections	with	TIA-1	and	LC3-RFP-GFP	were	implemented	to	determine	whether	RBPs	effect	autophagosomal	formation.	While	both	TIA-1	and	arsenite	enhance	the	size	of	autophagosomes,	arsenite,	and	particularly	arsenite	plus	TIA-1	significantly	increased	the	size	of	autophagosomes,	indicating	a	regulation	of	autophagy	by	SG	markers	in	a	stressed	state.	A	one-way	ANOVA	was	performed	for	analysis	in	Prism	(p<.001).	Scale	bar,	5	μm.	Autophagosomes	indicated	by	white	arrows.		 	
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Discussion	Our	study	begins	to	elucidate	the	relationship	of	RBPs	in	PD.	Prior	to	this	study,	the	pathology	of	RBPs	in	PD	had	yet	to	be	investigated.	As	we	began	to	study	this	connection	though	analysis	of	PD	and	PD-like	brains,	we	discovered	a	surprising	lack	of	SGs	in	the	PD	biology.	Previous	work	in	our	lab	examined	the	biology	of	RBPs	in	AD	(Vanderweyde	et	al.,	2012).	That	work	similarly	found	large	differences	in	RBPs	throughout	the	disease	life	cycle.	TIA-1,	TTP	and	G3BP	showed	the	largest	differences,	with	translocation	to	the	cytoplasm,	large	stress	granules	and,	in	the	case	of	TIA-1,	colocalization	with	Tau.	That	study	spurred	our	interest	in	examining	RBPs	in	PD	and	whether	the	same	RBPs	would	show	similar	changes	in	PD.	Our	findings	in	PD	and	related	diseases	differed	significantly	from	that	observed	in	AD.	Translocation	was	observed	from	the	nucleus	to	the	cytoplasm	with	TIA-1	and	HuD,	but	not	with	G3BP	and	TTP,	indicating	a	differential	regulation	of	RBPs	among	different	diseases.		There	are	over	800	RBPs	and	a	corresponding	flexibility	of	biological	responses	by	RBPs.	Although	the	response	of	TIA-1	SGs	is	muted	in	PD,	our	study	found	significant	changes	in	the	localization	of	HuD,	which	is	a	mostly	cytoplasmic	RBP	that	exhibits	an	even	higher	ratio	of	cytoplasmic	to	nuclear	localization	in	PD.	This	was	particularly	interesting	since	HuD	has	been	linked	to	age-at-onset	in	PD	(Noureddine	et	al.,	2015).	HuD,	also	known	as	ELAVL4,	is	a	neural	specific	RBP	that	binds	U-rich	regulatory	elements	in	3’-UTRs	of	mRNAs.	It	is	integral	in	inhibiting	mRNA	rapid	turnover	through	the	binding	of	these	U-rich	regions,	and	has	been	
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shown	specifically	to	bind	tau	mRNA	and	regulate	its	expression	levels	(Aranda-Abreu	et	al.,	1999).	Tau,	a	microtubule-associated	protein	is	genetically	linked	to	PD,	and	second	only	to	αsyn	in	attributable	risk	percentage	for	PD	(Lei	et	al.,	2010).	PD	patients	with	the	A53T	mutation	also	display	increased	tau	pathology	(Irwin	et	al.,	2013).	And	both	tau	and	αsyn	cross-seed	fibrillization	(Giasson	et	al.,	2003).	The	study	by	Aranda-Abreu	shows	that	knockdown	of	HuD	leads	to	a	decrease	in	the	levels	of	tau	(Aranda-Abreu	et	al.,	1999).	Our	study	reveals	HuD’s	increased	translocation	from	the	nucleus	to	the	cytoplasm	in	PD	compared	to	control	brains	with	no	change	in	expression	levels.	HuD	localizes	mainly	to	the	cytoplasm	(Kasashima	et	al.,	1999),	but	this	enhanced	expression	in	the	cytoplasm	could	indicate	an	over-activity	of	HuD	in	PD.	It	is	important	to	determine	whether	this	enhanced	expression	in	the	cytoplasm	correlates	with	expression	level	changes	of	tau,	especially	since	the	translocation	was	not	seen	as	strongly	in	PDD	and	DLB	brains.	The	strong	link	between	tau,	HuD	and	αsyn	present	an	important	link	that	could	lead	to	targeted	regulation	of	the	disease.		TIA-1	showed	the	strongest	translocation	from	the	nucleus	to	the	cytoplasm	in	diseased	brains.	However,	the	lack	of	TIA-1	positive	SGs	was	surprising	given	the	strong	formation	seen	in	AD	brains.	Examining	levels	of	TIA-1	in	PD	compared	to	age-matched	controls	revealed	no	significant	differences,	although	there	was	a	trend	towards	reduced	TIA-1	levels	in	PD	brains.	Decreased	levels	of	TIA-1	could	explain	the	lower	levels	of	SGs	in	PD	but	it	wouldn’t	account	for	the	absence	of	SGs	from	the	other	RBPs	(i.e.	HuD	which	maintained	steady	expression	levels	and	has	also	been	
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shown	to	form	stress	granules	in	response	to	stressors	such	as	heat	shock)	(Burry	et	al.,	2006).		A	decreased	level	of	SGs	could	reflect	either	decreased	production	or	increased	removal	of	SGs.	Although	the	mechanism	of	such	changes	is	currently	unclear,	the	prominence	of	αsyn	in	the	pathophysiology	of	PD	raises	the	possibility	that	the	accumulation	of	αsyn	contributes	to	the	reduced	SG	response.	This	led	us	to	examine	whether	the	lack	of	SGs	was	due	to	a	disruption	by	αsyn,	the	hallmark	protein	aggregate	in	the	pathology	of	PD,	or	to	autophagy,	the	cellular	mechanism	of	PD	shown	to	be	dysregulated.	Our	findings	showed	no	regulation	of	SG	biology	by	αsyn,	but	strong	mutual	regulation	of	autophagy	and	SGs.		Autophagy	and	RBPs	recently	have	emerged	in	the	field	of	neurodegeneration	as	possible	correlates	with	co-regulation	in	the	formation	of	SGs	and	autophagosomes.	Autophagy	appears	to	play	an	integral	role	in	SG	turnover	(Buchan	et	al.,	2013).	Valocin	containing	protein	(VCP)	plays	a	pivotal	role	in	linking	SGs	with	autophagy.	VCP	is	a	disaggregase	that	can	disperse	SGs;	knockdown	of	VCP	greatly	increased	SGs	throughout	HeLa	cells,	presumably	due	to	reduced	SG	turnover	(Buchan	et	al.,	2013,	Seguin	et	al.,	2014).	Mutations	in	VCP	cause	frontotemporal	lobar	degeneration,	with	associated	deficits	in	autophagy.	Another	group	outlined	the	regulation	of	HuD	over	autophagy	via	binding	to	the	3’-UTR	of	Atg5	mRNA	(Kim	et	al.,	2013).	They	showed	that	knockdown	of	HuD	decreased	Atg5	levels,	while	overexpressing	it	enhanced	those	levels,	leading	to	increased	autophagy.	This,	along	with	mutant	LRRK2,	could	provide	another	mechanism	
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accounting	for	increases	in	the	activity	of	some	autophagic	pathways	in	PD,	perhaps	as	a	compensatory	response	to	dysfunction	caused	by	αsyn	aggregation	in	other	pathways.	Strong	HuD	translocation	into	the	cytoplasm	would	potentially	upregulate	some	autophagic	pathways,	which	would	cause	a	reciprocal	reduction	in	the	levels	of	SGs	in	PD.	This	tight	regulation	between	RBPs	and	autophagy	could	be	a	potential	target	for	correcting	autophagic	dysfunction	in	PD.			The	prominent	role	of	αsyn	in	the	pathophysiology	of	PD	led	us	to	hypothesize	that	dysfunction	in	the	SG	pathway	might	be	caused	by	αsyn.	Previous	work	in	our	lab	demonstrated	strong	co-localization	of	TIA-1-positive	SGs	with	tau	in	AD	brains	(Vanderweyde	et	al.,	2012).	Since	tau	has	been	show	to	seed	the	fibrillization	of	αsyn	(Giasson	et	al.,	2015),	and	αsyn	is	the	pathologic	protein	of	fibrillization	in	PD,	we	were	interested	in	examining	whether	αsyn	played	a	role	in	regulating	TIA-1-postitive	SG	formation.	However,	multiple	independent	approaches	failed	to	show	a	demonstrable	effect	of	αsyn	on	SGs,	and	no	co-localization	of	Lewy	bodies	and	RBPs	was	observed.		Autophagy	is	regulated	by	multiple	intersecting	pathways.	Previous	studies	indicate	that	SG	levels	are	modulated	by	autophagy.	Our	studies	concur	with	the	published	literature	(Kim	et	al.,	2013).	Treatment	with	rapamycin,	which	increases	autophagy,	robustly	reduced	SG	levels.	αsyn	is	classically	thought	to	decrease	autophagy	in	the	PD	brain,	however	the	autophagic	response	might	be	more	nuanced	than	a	simple	on	or	off	response.	Compensatory	changes	in	the	autophagic	
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pathways	in	PD	could	possibly	reduce	the	SG	response,	producing	the	results	described	above.	Our	study	examines	the	interaction	between	SGs	and	autophagy	through	a	cell	culture	lens.	Activating	autophagy	led	to	a	decrease	in	SG	size	delineating	either	a	break	down	of	SGs	or	a	disruption	in	this	process.	Live	cell	imaging	should	be	conducted	to	differentiate	this	change.	Conversely,	overexpressing	TIA-1	under	conditions	of	stress	resulted	in	an	increase	in	the	number	of	autophagosomes.	This	novel	observation	of	co-regulation	provides	a	potentially	new	target	to	the	field	in	regulating	the	homeostasis	of	SGs	and	autophagy.		A	few	studies	have	shown	that	αsyn	is	degraded	by	autophagy	(Lee	et	al.,	2004,	Riedel	et	al.,	2010),	while	others	show	that	it	might	inhibit	autophagy	(Winslow	et	al.,	2010).	This	connection	needs	to	be	further	clarified,	since	both	αsyn	and	autophagy	are	deregulated	in	PD.	Our	study	shows	that	αsyn	does	not	effect	SG	formation,	but	that	autophagy	and	the	SG	pathway	are	important	mechanisms	for	co-regulation	of	these	two	processes	that	diverge	in	diseased	states.	As	further	studies	on	this	association	continue,	there	may	yet	be	a	connection	between	some	RBPs	and	αsyn.	HuD	is	a	prime	candidate	for	this	continued	exploration	due	to	it’s	influences	in	PD.	This	study	expounds	on	the	relationship	of	SGs	and	autophagy	in	PD.	Moving	forward,	regulating	these	pathways	may	be	an	important	innovation	in	the	field.			
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CHAPTER	FOUR	–	CONCLUSION		 	
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This	body	of	work	highlights	a	novel	connection	between	PD-associated	innervation	of	autophagy,	and	the	pathogenesis	of	SGs	in	PD.	We	hypothesized	that	HDAC6	and	LRRK2	interact	to	regulate	autophagy,	and	determined	that	PD-associated	LRRK2	mutations	require	HDAC6	for	its	regulation	of	autophagy.	We	further	hypothesized	that	the	pathophysiology	of	PD	leads	to	differential	expression	and	localization	of	RBPs	implicated	in	the	SG	response.	Differential	expression	was	observed	with	TIA-1	and	HuD	in	PD	brains,	as	were	notably	low	levels	of	SGs.	This	lack	of	SG	is	likely	the	result	of	a	co-regulation	of	the	autophagy	pathway	and	SG	response.	Our	challenge	is	to	tie	these	findings	into	a	singular	mechanism	by	which	disease	progression	may	be	halted.		PD	is	a	wide-spread	endemic	with	all	pharmacological	interventions	since	the	50s	focused	solely	on	targeting	dopamine	in	the	CNS.	Current	therapeutics	combat	this	dysregulation	by	flooding	the	CNS	with	dopamine.	This	is	a	quick	fix,	and	does	nothing	to	combat	the	underlying	cause	of	the	disease.	fWith	a	growing	population	of	elderly	people,	the	occurrence	of	PD	will	continue	to	rise.	The	above	studies	highlight	potentially	new	targets	in	this	field	that	could	lead	to	wholly	new	therapeutics.		Genomics	research	in	the	field	has	identified	LRRK2	as	an	important	correlate	to	disease	progression	with	the	G2019S	mutation	present	in	5-6%	of	familial	cases	and	1-2%	of	sporadic	cases	(Li	et	al.,	2014).	Based	on	the	relevance	of	LRRK2	in	PD,	revealing	the	LRRK2	regulatory	network	allows	for	greater	understanding	of	associated	transcripts	and	their	functions.	HDAC6,	as	the	most	
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closely	linked	in	our	network	to	PD,	defines	an	exciting	connection	between	LRRK2	and	HDAC6	in	PD,	and	autophagy,	the	bridge	between	them.	LRRK2	and	HDAC6	have	both	been	shown	to	enhance	autophagy	at	the	initiation	and	autophagolysosomal	fusion	stage	(Plowey	et	al.,	2008,	Lee	et	al.,	2010).	Our	finding	defines	a	potential	mechanism	by	which	this	might	occur.	Phosphorylation	of	HDAC6	by	LRRK2	could	enhance	the	deacetylase	activity	of	HDAC6	since	other	substrates	that	phosphorylate	HDAC6	have	been	shown	to	enhance	its	deacetylase	activity	(Du	et	al.,	2015).	This	enhanced	deacetylase	activity	could	therein	lead	to	its	enhanced	control	over	the	fusion	of	the	autophagosome	to	the	lysosome,	and	perhaps	an	upregulation	of	this	stage	in	autophagy.	It	would	be	interesting	to	examine	whether	the	LRRK2-HDAC6	complex	at	the	fusion	stage	of	autophagy	binds	with	increased	propensity	when	LRRK2	mutations	are	present.	Our	finding	of	actin	as	a	first	neighbor	of	LRRK2	and	HDAC6	is	especially	poignant	since	HDAC6	increases	autophagosome-lysosomal	fusion	through	recruitment	of	an	F-actin	network.	And	deacetylation	activity	within	this	network	is	essential	for	fusion	(Lee	et	al.,	2010).	With	increased	kinase	activity	in	LRRK2	mutants,	upregulating	autophagic	formation,	as	well	as	enhancing	HDAC6	deacetylase	activity	as	trends	from	our	study	show,	it	is	conceivable	that	overactivation	through	this	pathway	leads	to	the	dysregulation	of	autophagy	seen	in	PD.	Inhibiting	HDAC6	in	this	overactive	pathway	may	be	a	promising	target	in	PD.		In	AD	autophagy	is	disrupted.	One	group	found	AD	associated	mutations	disrupt	autophagic	flux,	while	another	found	autophagic	proteins	to	be	
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downregulated	in	AD	(Orr	et	al.,	2013).		A	study	by	Wolfe	et	al.,	2013	outlines	the	failure	of	lysosomal	degradation	of	materials	due	to	poor	buffering	and	high	pH	(Wolfe	et	al.,	2013).	These	autophagic	dysfunctions	differ	from	PD	in	which	increased	lysosomal	acidity	is	observed	upon	overexpression	of	the	G2019S	mutation	(Henry	et	al.,	2015).	While	this	group	found	lysosomes	to	have	a	low	pH	upon	overexpression	of	mutant	LRRK2	their	findings	on	the	degradative	capacity	of	the	lysosome	was	conflicting.	Other	PD	associated	mutations	do	lead	to	dysfunctional	lysosomes	such	as	mutations	in	ATP13A2	and	GBA.	ATP13A2	is	a	transmembrane	lysosomal	ATPase	that	expresses	mainly	in	the	brain	(Yang	et	al.,	2014).	PD	associated	mutations	in	this	gene	lead	to	reduced	degradative	properties	of	the	lysosome	(Dehay	et	al.,	2013).	Mutations	in	the	lysosomal	enzyme	glucocerebrosidase	(GBA)	lead	to	the	lysosomal	storage	disorder,	Gaucher’s	disease.	Heterozygous	mutations	of	this	gene	have	also	been	correlated	with	PD,	but	are	more	closely	related	to	DLB	(Irwin	et	al.,	2014).	GBA	mutations	associated	with	PD	lead	to	an	accumulation	of	glucosylceramide	in	the	lysosome	(Dehay	et	al.,	2013).	This	is	an	interesting	finding	because	it	points	to	another	potential	overload	of	the	autophagic	system.	As	seen	in	prionogenic	diseases,	prions	can	accumulate	in	the	lysosome	blocking	its	ability	to	degrade	other	cargo	(Whatley	et	al.,	2008).	This	study	also	found	an	efflux	of	prions	via	exosomes	due	to	an	inability	of	the	lysosome	to	degrade	these	stable	proteins.	αsyn,	also	shown	to	have	prionogenic	properties	(Giasson	et	al.,	2002),	may	block	degradation	of	lysosomal	cargo	via	a	similar	build-up.	It	would	be	interesting	to	determine	whether	exosomal	release	of	αsyn	fibrils	
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happens	via	a	similar	mechanism.		The	difference	in	autolysosomal	function	in	PD	and	AD	are	important	findings	not	only	because	they	vary	from	PD-associated	autolysosomal	dysfunction,	but	because	they	vary	in	a	way	that	highlights	the	mechanistic	differences	we	see	with	RBPS	in	PD.	Our	findings	of	differential	regulation	of	certain	RBPs	and	a	disrupted	SG	pathway	in	PD	is	exciting	because	it	highlights	a	novel	mechanism	and	target	of	dysregulation	in	PD	that	hadn’t	been	previously	considered.	Strong	TIA-1	positive	SG	in	AD	brains	led	us	to	examine	whether	these	SGs	were	present	in	PD.	However,	they	were	not	present.	Upon	further	evaluation	this	could	be	a	differential	regulation	by	autophagy.	As	mentioned	above,	many	of	the	mutations	and	correlates	of	AD	lead	to	a	downregulation	of	autophagy.	Whereas,	in	PD,	many	of	the	mutations	and	processes	lead	to	an	enhancement	of	this	pathway	at	the	initiation	and	fusion	stage,	particularly	the	G2019S	and	R1441C	mutations	(Plowey	et	al.,	2008,	Bravo-San	Pedro	et	al.,	2012).	Even	αsyn	leads	to	an	upregulation	of	autophagy	via	inhibition	of	CMA	.	One	group	found	that	WT	αsyn	overexpression	leads	to	oligomers	that	cannot	use	CMA.	Any	blockage	of	CMA	leads	to	an	upregulation	of	autophagy,	as	the	group	found	by	further	studying	the	A53T	mutation	which	tightly	bound	LAMP-2A	receptors	but	failed	to	cross	the	lysosomal	membrane,	inevitably	blocking	CMA,	inhibiting	it	and	leading	to	a	compensatory	increase	in	autophagy	(Day	et	al.,	2012).				 Strong	expression	of	HuD	in	PD	cytoplasm	may	be	another	mechanism	by	which	autophagic	initiation	is	upregulated.	As	mentioned	above,	a	group	found	HuD	
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binds	the	3’	end	of	atg5	mRNA,	preventing	its	degradation	and	upregulating	its	expression	levels	(Kim	et	al.,	2014).	They	further	found	that	inhibiting	autophagy	with	3MA	or	baflomycin	lead	to	an	increase	in	autophagy.	This	parallels	the	levels	of	SGs	we	see	in	AD	and	PD.	Paired	with	the	knowledge	that	HuD	is	associated	with	age	at	onset	of	PD,	our	findings	hint	to	a	prime	target	for	downregulating	autophagic	induction	in	PD.			 There	remains	a	wealth	of	information	to	be	captured	on	the	dysregulation	of	autophagy	in	neurodegenerative	disease.	Cuervo’s	group	highlights	an	important	distinction	between	quality	control	autophagy	and	starvation	induced	autophagy,	while	pointing	out	that	the	mechanistic	differences	between	these	disparate	inductions	is	unknown	(Cuervo	et	al.,	2007).	HDAC6	is	the	first	protein	to	be	shown	to	play	a	role	in	only	one	of	these	two	separate	pathways,	as	HDAC6	played	no	role	in	starvation	induced	autophagy	(Cuervo	et	al.,	2007).	This	makes	HDAC6	another	prime	candidate	for	regulation	of	autophagy	since	quality	control	autophagy	is	the	main	form	of	autophagy	in	the	brain.	Other	tissues	rely	largely	on	starvation	induced	autophagy	(Mizushima	et	al.,	2003).	HDAC6	is	also	present	in	SGs	and	may	be	integral	for	targeting	them	to	aggresomes	for	degradation	(Seguin	et	al.,	2014).	A	few	groups	have	shown	the	reciprocal	relationship	between	valosin	containing	protein	(VCP)	and	HDAC6	(Boyault	et	al.,	2007,	Seguin	et	al.,	2014).	VCP	is	an	ubiquitin	selective	chaperone	and	ATPase	that	is	also	important	for	autophagic	flux	(Seguin	et	al.,	2014).	High	VCP	over	HDAC6	levels	causes	HDAC6	unbiding	from	ubiquitin	and	decreased	degradation	of	formerly	bound	targets	(Boyault	et	al.,	
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2007).	It	would	be	interesting	to	test	whether	HDAC6	modulates	SG	ubiquitination,	and	whether	upregulating	levels	of	VCP	might	reverse	any	enhanced	degradation	by	HDAC6,	especially	since	VCP	has	been	shown	to	be	important	for	autophagic	degradation	of	SGs	(Buchan	et	al.,	2013).			 While	αsyn	showed	no	effect	on	SG	formation	in	our	hands,	future	studies	should	further	explicate	the	importance	of	this	protein	in	the	autophagic-RBP	pathway.	A	finding	by	Nilsson	et	al.,	2013	presented	a	novel	finding	on	autophagy	in	AD	(Nilsson	et	al.,	2013).	This	group	found	that	autophagy	secretes	abeta	from	cells	allowing	for	the	formation	of	extracellular	plaques.	Whereas	mice	with	KO	in	atg	genes	showed	no	extracellular	plaques.	This	is	an	incredible	finding	because	it	highlights	the	importance	of	tightly	regulating	autophagy.	Whether	autophagy	secretes	amyloid	beta	under	normal	conditions	or	does	this	as	a	compensatory	mechanism	against	lysosmal	dysfunction	in	AD,	this	is	a	finding	that	needs	to	be	replicated	in	PD.	Again,	if	αsyn	is	similarly	transported	out	of	cells,	this	could	be	the	mechanism	by	which	fibrils	are	seeded	throughout	the	brain.	It	could	point	to	another	potentially	benefit	of	downregulating	autophagy	in	PD.	Enhancing	lysosomal	function	as	a	way	of	unburdening	the	insult	of	disease-linked	upregulation	of	autophagic	initiation	and	flux	could	be	another	beneficial	target	in	PD.	However,	dopamine	neurons	are	already	energetically	stressed,	and	downregulating	an	overactive	stage	of	autophagic	flux	would	be	a	safer	target.						 Our	findings	highlight	a	novel	pathway	in	which	autophagic	dysfunction	is	exacerbated	in	PD	(Figure	4.1).	Multiple	PD-associated	mutations	including	the	
		
95 
A53T,	G2019S	and	R1441C	mutations	lead	to	an	upregulation	of	the	initiation	and	the	fusion	stage	of	autophagy	that	leads	to	dysregulation	in	disease.	The	SG	pathway	also	leads	to	upregulation	of	autophagy	and	subsequent	breakdown	of	SGs.	HuD	and	HDAC6	are	two	important	proteins	in	this	process	that	similarly	lead	to	upregulation	of	autophagy.	Future	studies	and	therapeutics	should	look	to	these	two	proteins	as	a	way	of	downregulating	autophagy	and	potentially	abating	the	progression	of	pathology	in	PD.		 	
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Figure	4.1.	Dysregulation	of	autophagy	in	PD.	αsyn	blocks	CMA	via	irreversible	binding	to	LAMP-2A,	which	prevents	other	proteins	from	crossing	into	the	lysosome.	Loss	of	αsyn	degradation	by	CMA	leads	to	cytoplasmic	accumulation	of	
αsyn	monomers	and	subsequent	oligomerization.	Inhibition	of	CMA	leads	to	compensatory	upregulation	of	autophagic	initiation,	and	degradation	of	αsyn	by	autophagy.	High	levels	of	αsyn	leads	to	cellular	stress	and	translocation	and	TIA-1	into	the	cytoplasm	where	it	forms	SGs.	HuD,	localized	to	the	cytoplasm,	also	increases	autophagic	initiation	by	stabilizing	mRNA	and	increasing	expression	of	autophagy	dependent	proteins	such	as	atg5.	Mutant	LRRK2	complexes	with	HDAC6,	leading	to	the	hyperphosphorylation	of	HDAC6,	and	its	enhanced	deacetylase	activity.	This	complex	enhances	fusion	of	the	autophagosome	to	the	lysosome.	p-HDAC6,	present	in	SGs,	may	also	enhance	targeting	of	SGs	for	degradation.	Over-activity	of	this	pathway	may	lead	to	ATP	depletion	and	cellular	dysfunction	due	to	the	overwhelming	ATP	burden	required	by	the	lysosome	(adapted	from	Lynch-Day	et	al.,	2012).			
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